Equities Analysts Issue Forecasts for argenx Q4 Earnings

argenx SE (NASDAQ:ARGX - Free Report) - Investment analysts at Wedbush issued their Q4 2026 earnings estimates for argenx in a report issued on Monday, June 16th. Wedbush analyst D. Nierengarten expects that the company will earn $7.81 per share for the quarter. Wedbush currently has a "Outperform" rating and a $715.00 price target on the stock. The consensus estimate for argenx's current full-year earnings is $3.13 per share.

Several other equities research analysts also recently weighed in on ARGX. Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Sanford C. Bernstein raised argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Baird R W raised argenx from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and set a $720.00 price target on shares of argenx in a report on Tuesday, June 10th. Finally, Wells Fargo & Company increased their price target on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, argenx presently has a consensus rating of "Buy" and an average price target of $709.18.

argenx Trading Down 4.6%

ARGX stock opened at $551.22 on Tuesday. The company has a market capitalization of $33.66 billion, a P/E ratio of -626.39 and a beta of 0.39. argenx has a twelve month low of $377.47 and a twelve month high of $678.21. The business has a 50 day simple moving average of $587.56 and a 200-day simple moving average of $611.16.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%.

Institutional Trading of argenx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARGX. FMR LLC boosted its stake in argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after buying an additional 824,750 shares during the last quarter. Capital World Investors lifted its position in argenx by 5.1% during the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock worth $1,099,002,000 after acquiring an additional 86,687 shares in the last quarter. RTW Investments LP increased its holdings in argenx by 2.9% during the 4th quarter. RTW Investments LP now owns 673,497 shares of the company's stock worth $414,201,000 after purchasing an additional 19,067 shares during the last quarter. Clearbridge Investments LLC increased its holdings in argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock worth $387,344,000 after purchasing an additional 40,330 shares during the last quarter. Finally, Lord Abbett & CO. LLC increased its holdings in argenx by 33.2% during the 1st quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company's stock worth $162,585,000 after purchasing an additional 68,498 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.